Lazard Freres Gestion S.A.S. boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 28.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 890,953 shares of the company's stock after buying an additional 197,337 shares during the quarter. Zoetis accounts for approximately 3.7% of Lazard Freres Gestion S.A.S.'s holdings, making the stock its 7th biggest holding. Lazard Freres Gestion S.A.S. owned about 0.20% of Zoetis worth $174,074,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Silvercrest Asset Management Group LLC grew its position in shares of Zoetis by 33.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 12,793 shares of the company's stock valued at $2,165,000 after buying an additional 3,193 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Zoetis during the 1st quarter valued at about $883,000. B. Riley Wealth Advisors Inc. grew its position in shares of Zoetis by 17.4% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 16,016 shares of the company's stock valued at $2,786,000 after buying an additional 2,370 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Zoetis by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 743,807 shares of the company's stock valued at $125,860,000 after buying an additional 2,872 shares during the last quarter. Finally, Tidal Investments LLC grew its position in shares of Zoetis by 9.8% during the 1st quarter. Tidal Investments LLC now owns 8,703 shares of the company's stock valued at $1,471,000 after buying an additional 776 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.
Zoetis Price Performance
ZTS stock traded down $3.01 on Tuesday, hitting $175.70. 2,539,501 shares of the company's stock traded hands, compared to its average volume of 2,551,124. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock has a market cap of $79.27 billion, a price-to-earnings ratio of 33.03, a P/E/G ratio of 2.71 and a beta of 0.90. The stock has a fifty day moving average of $184.91 and a 200-day moving average of $180.84. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.
Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.36 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis's dividend payout ratio (DPR) is presently 32.52%.
Analysts Set New Price Targets
A number of brokerages recently weighed in on ZTS. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a research report on Wednesday, September 18th. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Piper Sandler upped their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 14th. Finally, Argus upgraded shares of Zoetis to a "strong-buy" rating in a research report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $221.44.
Read Our Latest Report on Zoetis
Zoetis Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
